The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions

Summary

Since activation of the haemostatic system is an important feature of the wound healing response triggered by arterial injury, variations in genes involved in thrombus formation may play a role in restenosis after percutaneous coronary interventions (PCI). Therefore, our aim was to examine the relationship between polymorphisms that are known to play a role in the haemostatic system and the risk of clinical restenosis in the GENetic DEterminants of Restenosis (GENDER) study,a multicenter prospective study design that enrolled 3,104 consecutive patients after successful PCI. Target vessel revascularization (TVR) was the primary endpoint. All patients were genotyped for six polymorphisms in the Factor II, Factor V, Factor VII and PAI-1 genes. The PAI-1 4G variant was associated with an increased risk ofTVR. When compared to 5G/5G homozygotes, heterozygous patients were at higher risk for TVR (HR: 1.46, 95%CI: 1.05–2.03), whereas patients with the 4G/4G genotype had an even further increased risk (HR: 1.69, 95%CI: 1.19–2.41). In contrast, the factor V 506Gln (factor V Leiden) amino acid substitution was associated with a decreased risk of TVR (HR: 0.41, 95%CI: 0.19–0.86). Our findings indicate that polymorphisms in the factorV and PAI-1 genes may play a role in the process of restenosis.

Keywords

Restenosis - polymorphisms - coagulation factors

• References

• 1 Weintraub WS, Kosinski AS, Brown III CL. et al. Can restenosis after coronary angioplasty be predicted from clinical variables?. J Am Coll Cardiol 1993; 21: 6-14.
• 2 Agema WR, Jukema JW, Pimstone SN. et al. Genetic aspects of restenosis after percutaneous coronary interventions: towards more tailored therapy. Eur Heart J 2001; 22: 2058-2074.
• 3 Agema WRP, Monraats PS, Zwinderman AH. et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004; 25: 1163-1170.
• 4 Monraats PS, Rana JS, Zwinderman AH. et al. –455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost 2005; 93: 564-569.
• 5 Rana JS, Monraats PS, Zwinderman AH. et al. Preprocedural levels of erythrocyte sedimentation rate (ESR) and risk of clinical restenosis in patients with percutaneous coronary intervention and coronary stent placement. Thromb Haemost 2005; 94: 892-894.
• 6 Saiki RK, Walsh PS, Levenson CH. et al. Genetic analysis of amplified DNA with immobilized sequence- specific oligonucleotide probes. Proc Natl Acad Sci USA 1989; 86: 6230-6234.
• 7 Pannacciulli N, De MV, Marino R. et al. Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 2002; 10: 717-725.
• 8 Herlihy OM, Barrow BA, Grant PJ. et al. Hyperglycaemic siblings of Type II (non--dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia 2002; 45: 635-641.
• 9 Schalkwijk CG, Stehouwer CD. PAI-1 inhibition in obesity and the metabolic syndrome: a promising therapeutic strategy. Thromb Haemost 2006; 96: 698-699.
• 10 Juhan-Vague I, Morange PE, Frere C. et al. The plasminogen activator inhibitor-1 –675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma pro and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost 2003; 1: 2322-2329.
• 11 Ortlepp JR, Hoffmann R, Killian A. et al. The 4G/5G promotor polymorphism of the plasminogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol 2001; 24: 585-591.
• 12 Kathiresan S, Gabriel SB, Yang Q. et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005; 112: 1728-1735.
• 13 Diamanti-Kandarakis E, Palioniko G, Alexandraki K. et al. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004; 150: 793-798.
• 14 Asselbergs FW, Williams SM, Hebert PR. et al. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 2006; 96: 471-477.
• 15 Castello R, Espana F, Vazquez C. et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006; 117: 487-492.
• 16 Burzotta F, Iacoviello L, Di Castelnuovo A. et al. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study. J Thromb Thrombolysis 2003; 16: 149-154.
• 17 Festa A, D’Agostino Jr. R, Rich SS. et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the insulin Resistance Atherosclerosis Study. Circulation 2003; 107: 2422-2427.
• 18 Huber K, Jorg M, Probst P. et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67: 209-213.
• 19 Sakata K, Miura F, Sugino H. et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1-6.
• 20 Ishiwata S, Tukada T, Nakanishi S. et al. Postangioplasty restenosis: platelet activation and the coagulation- fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387-392.
• 21 Lins M, Zurborn KH, Dau O. et al. Coagulation activation in patients undergoing directional coronary atherectomy. Thromb Res 1997; 86: 433-441.
• 22 Ishiwata S, Nakanishi S, Nishiyama S. et al. Prevention of restenosis by bezafibrate after successful coronary angioplasty. Coron Artery Dis 1995; 6: 883-889.
• 23 Prisco D, Fedi S, Antonucci E. et al. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 2001; 104: 181-186.
• 24 Bottiger C, Koch W, Lahn C. et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J 2003; 146: 855-861.
• 25 Fay WP. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med 2004; 14: 196-202.
• 26 Christ G, Kostner K, Zehetgruber M. et al. Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?. J Thromb Thrombolysis 1999; 7: 277-285.
• 27 Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
• 28 Rossignol P, Angles-Cano E, Lijnen HR. Plasminogen activator inhibitor-1 impairs plasminogen activation- mediated vascular smooth muscle cell apoptosis. Thromb Haemost 2006; 96: 665-670.
• 29 Volzke H, Grimm R, Robinson DM. et al. Candidate genetic markers and the risk of restenosis after coronary angioplasty. Clin Sci (Lond) 2004; 106: 35-42.
• 30 Doggen CJ, Cats VM, Bertina RM. et al. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-1041.
• 31 Ye Z, Liu EH, Higgins JP. et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658.
• 32 Kerlin BA, Yan SB, Isermann BH. et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102: 3085-3092.
• 33 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• 34 Haley M, Cui X, Minneci PC. et al. Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness. Curr Opin Infect Dis 2004; 17: 205-211.
• 35 Van de Wouwer M, Collen D, Conway EM. Thrombomodulin- protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004; 24: 1374-1383.
• 36 Monraats PS, Pires NM, Agema WR. et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005; 112: 2417-2425.
• 37 Monraats PS, Pires NM, Schepers A. et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 2005; 19: 1998-2004.
• 38 Gabriely I, Yang XM, Cases JA. et al. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis 2002; 160: 115-122.
• 39 He G, Bruun JM, Lihn AS. et al. Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro. Biochem Biophys Res Commun 2003; 310: 878-883.
• 40 Weiler H, Kerlin B, Lytle MC. Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Crit Care Med 2004; 32: S233-S238.